BR112013029334A2 - método de produção de megacariócitos poliploidizados, composição de células sanguíneas, método de produção de uma plaqueta, plaqueta e produto de sangue - Google Patents

método de produção de megacariócitos poliploidizados, composição de células sanguíneas, método de produção de uma plaqueta, plaqueta e produto de sangue

Info

Publication number
BR112013029334A2
BR112013029334A2 BR112013029334-9A BR112013029334A BR112013029334A2 BR 112013029334 A2 BR112013029334 A2 BR 112013029334A2 BR 112013029334 A BR112013029334 A BR 112013029334A BR 112013029334 A2 BR112013029334 A2 BR 112013029334A2
Authority
BR
Brazil
Prior art keywords
platelet
production method
megac
pli
cell composition
Prior art date
Application number
BR112013029334-9A
Other languages
English (en)
Other versions
BR112013029334B1 (pt
Inventor
Nakauchi Hiromitsu
Eto Koji
Takayama Naoya
Nakamura Sou
Original Assignee
The University Of Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tokyo filed Critical The University Of Tokyo
Publication of BR112013029334A2 publication Critical patent/BR112013029334A2/pt
Publication of BR112013029334B1 publication Critical patent/BR112013029334B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

mé todo de produção de megacari óci tos poli ploi di zados, composi ção de cé lulas sanguíneas, mé todo de produção de uma plaqueta, plaqueta e produto de sangue. a pr es ent e i nv ençã o r ef er e- s e à um mét odo de pr omov er a pol i pl oi di z açã o de megac ar i óc i t os e, por t ant o, pr oduçã o de megac ar i óc i t os al t ament e pol i pl oi di z ados , um mét odo de pr oduçã o ef i c i ent e de pl aquet as a par t i r de megac ar i óc i t os ' pol i pl oi di z ados e s i mi l ar es . a pr es ent e i nv ençã o f or nec e um mét odo de pr oduçã o de megac ar i óc i t os pol i pl oi di z ados c ompr eendendo uma et apa de f or çar a ex pr es s ã o de um genes upr es s or de apopt os e em megac ar i óc i t os ant es da pol i pl oi di z açã o e o c ul t i v o das c él ul as r es ul t ant es .
BR112013029334-9A 2011-05-13 2012-05-11 Método de produção de megacariócitos poliploidizados e método de produção de plaquetas BR112013029334B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011108253 2011-05-13
JP2011-108253 2011-05-13
PCT/JP2012/062217 WO2012157586A1 (ja) 2011-05-13 2012-05-11 多核化巨核球細胞、及び血小板の製造方法

Publications (2)

Publication Number Publication Date
BR112013029334A2 true BR112013029334A2 (pt) 2019-03-12
BR112013029334B1 BR112013029334B1 (pt) 2022-01-18

Family

ID=47176904

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029334-9A BR112013029334B1 (pt) 2011-05-13 2012-05-11 Método de produção de megacariócitos poliploidizados e método de produção de plaquetas

Country Status (14)

Country Link
US (2) US9738906B2 (pt)
EP (1) EP2708597B1 (pt)
JP (1) JP5824760B2 (pt)
KR (1) KR101572344B1 (pt)
CN (1) CN103814126B (pt)
AU (1) AU2012256880B2 (pt)
BR (1) BR112013029334B1 (pt)
CA (1) CA2836073C (pt)
DK (1) DK2708597T3 (pt)
ES (1) ES2659262T3 (pt)
IL (1) IL229382B (pt)
RU (1) RU2606764C2 (pt)
SG (1) SG195007A1 (pt)
WO (1) WO2012157586A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
ES2896354T3 (es) * 2012-12-21 2022-02-24 Astellas Inst For Regenerative Medicine Métodos para la producción de plaquetas a partir de células madre pluripotentes
US20160002599A1 (en) * 2013-02-08 2016-01-07 Kyoto University Production methods for megakaryocytes and platelets
WO2014168255A1 (ja) * 2013-04-12 2014-10-16 国立大学法人京都大学 巨核球の成熟化促進物質
JP6551963B2 (ja) * 2014-05-14 2019-07-31 国立大学法人京都大学 巨核球前駆細胞の製造方法
US10112977B2 (en) 2014-06-23 2018-10-30 Toagosei Co., Ltd. Peptide for inducing multinucleation in cells, and use therefor
US20180051260A1 (en) * 2015-04-14 2018-02-22 Kyoto University Method for Producing Stem Cell Clones Suitable for Induction of Differentiation into Somatic Cells
KR102600772B1 (ko) * 2015-06-16 2023-11-13 고쿠리츠 다이가쿠 호진 교토 다이가쿠 고기능성 혈소판의 제조 방법
AU2016324365A1 (en) * 2015-09-15 2018-04-12 Megakaryon Corporation Platelet production method using rotary agitation culturing method
RU2766177C2 (ru) * 2015-10-14 2022-02-08 Мегакарион Корпорейшн Способ получения очищенных тромбоцитов
EP3372674B1 (en) * 2015-11-02 2020-10-07 Megakaryon Corporation Method for preparing platelets using reciprocating stirring device
JP6879511B2 (ja) 2016-01-29 2021-06-02 国立大学法人京都大学 血小板産生促進剤及びそれを用いた血小板の製造方法
EP3409774A4 (en) 2016-01-29 2019-10-23 Kyoto University SCREENING PROCESS FOR PROMOTER OF THROMBOZYTE PRODUCTION
JP7104636B2 (ja) * 2016-06-27 2022-07-21 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル ミトコンドリア生物の活性化による血小板産生刺激
EP3594325A4 (en) * 2017-03-06 2020-12-09 Kyoto University PLATELET PRODUCTION PROCESS
WO2019009364A1 (ja) 2017-07-07 2019-01-10 国立大学法人京都大学 血小板の製造方法および製造装置、ならびに血小板の製造装置における運転条件の決定方法
US20200216808A1 (en) 2017-09-19 2020-07-09 Megakaryon Corporation Method for producing platelets, method for producing platelet product, and method for producing blood product
WO2019059235A1 (ja) 2017-09-19 2019-03-28 株式会社メガカリオン 精製血小板の製造方法、血小板製剤の製造方法、血液製剤の製造方法、血小板保存液、血小板保存剤および血小板の保存方法
CN110373386A (zh) * 2019-07-02 2019-10-25 中国医学科学院血液病医院(中国医学科学院血液学研究所) Jak激酶抑制剂在制备促进多能干细胞诱导产生巨核细胞和血小板的产品中的用途
WO2021075568A1 (ja) * 2019-10-17 2021-04-22 国立大学法人千葉大学 巨核球前駆細胞又は巨核球細胞の製造方法
CN110564687B (zh) * 2019-11-05 2020-04-03 诺未科技（北京）有限公司 用于扩增造血干细胞的组合物、培养基、方法和试剂盒
CN115023233A (zh) * 2019-12-12 2022-09-06 国立大学法人千叶大学 包含巨核细胞和血小板的冷冻干燥制剂
EP4063489A4 (en) * 2019-12-13 2024-02-28 Megakaryon Corp COMPOSITION AND USE THEREOF
US20230062476A1 (en) * 2020-02-28 2023-03-02 Otsuka Pharmaceutical Co., Ltd. Genetically modified megakaryocyte, modified platelet, and methods respectively for producing said genetically modified megakaryocyte and said modified platelet
JP2021180620A (ja) 2020-05-18 2021-11-25 株式会社マイオリッジ 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地
WO2022092169A1 (ja) 2020-10-27 2022-05-05 国立大学法人 長崎大学 骨形成組成物およびその用途
CN117500913A (zh) 2021-06-18 2024-02-02 株式会社美加细胞 血小板产生能力得到增强的多核化巨核细胞的制造方法、血小板的制造方法、血小板制剂的制造方法及血液制剂的制造方法
EP4365283A1 (en) 2021-06-30 2024-05-08 National University Corporation Chiba University Method for improving proliferative properties of common myeloid progenitor cells (cmp) or myelocytic progenitor cells
WO2024076030A1 (ko) * 2022-10-05 2024-04-11 주식회사 듀셀바이오테라퓨틱스 혈소판의 제조 방법
KR20240055673A (ko) 2022-10-18 2024-04-29 의료법인 성광의료재단 줄기세포에서 혈소판 전구세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951199B (en) * 1994-02-14 1996-08-14 Kirin Brewery Protein having tpo activity
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
CN1286970C (zh) * 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 由脐血cd34+细胞体外诱导生成巨核细胞的方法
US8058064B2 (en) 2006-10-04 2011-11-15 The University Of Tokyo Sac-like structure enclosing hematopoietic progenitor cells produced from ES cells and method for preparing blood cells
JP2009213645A (ja) * 2008-03-10 2009-09-24 Barudan Co Ltd シークインテープ供給装置
JP5617631B2 (ja) 2008-04-01 2014-11-05 国立大学法人東京大学 ｉＰＳ細胞からの血小板の調製方法
KR101667834B1 (ko) * 2009-09-15 2016-10-20 고쿠리츠다이가쿠호우진 도쿄다이가쿠 분화 세포의 신규 제조법
EP2686420B1 (en) * 2011-03-18 2017-03-01 New York Blood Center, Inc. Megakaryocyte and platelet production from stem cells
RU2482870C1 (ru) * 2012-02-27 2013-05-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Средство, индуцирующее дифференцировку стволовых кроветворных клеток в тромбоциты

Also Published As

Publication number Publication date
US10533185B2 (en) 2020-01-14
IL229382B (en) 2018-02-28
CN103814126A (zh) 2014-05-21
EP2708597A1 (en) 2014-03-19
IL229382A0 (en) 2014-01-30
KR20140029488A (ko) 2014-03-10
AU2012256880A1 (en) 2013-12-12
JPWO2012157586A1 (ja) 2014-07-31
CA2836073A1 (en) 2012-11-22
SG195007A1 (en) 2013-12-30
RU2606764C2 (ru) 2017-01-10
AU2012256880B2 (en) 2015-09-17
RU2013154962A (ru) 2015-06-20
DK2708597T3 (en) 2018-02-05
KR101572344B1 (ko) 2015-11-26
EP2708597A4 (en) 2014-11-19
CN103814126B (zh) 2017-10-24
US20140127815A1 (en) 2014-05-08
US20180016597A1 (en) 2018-01-18
EP2708597B1 (en) 2017-11-15
WO2012157586A1 (ja) 2012-11-22
CA2836073C (en) 2019-07-23
JP5824760B2 (ja) 2015-12-02
US9738906B2 (en) 2017-08-22
ES2659262T3 (es) 2018-03-14
BR112013029334B1 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
BR112013029334A2 (pt) método de produção de megacariócitos poliploidizados, composição de células sanguíneas, método de produção de uma plaqueta, plaqueta e produto de sangue
BR112016025516A2 (pt) composições para controle de mosquito e usos das mesmas
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
NI200900159A (es) Moduladores de 2-aminopirimidina del receptor de histamina h4.
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
GT201500069A (es) Piridinonas bicìclicas novedosas
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
ECSP13012411A (es) Composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona
BR112013026965A2 (pt) método para inibir micro-organismos prejudiciais e composição formadora de barreira para os mesmos
WO2014066916A3 (en) Compositions and methods for safe treatment of rhinitis
EA201891115A1 (ru) Новая фармацевтическая композиция, содержащая частицы, содержащие комплекс двухнитевого полирибонуклеотида и полиалкиленимина
CL2008002747A1 (es) Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros.
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
PE20142457A1 (es) Compuestos heterociclicos y sus usos
BR112015008954A2 (pt) composições de ciclodextrina alquilatada e processos para preparação e uso das mesmas
BR112015013783A2 (pt) quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
BR112016015190A2 (pt) Composição farmacêutica não contendo antioxidante e método de preparação da mesma
BR112017011012A2 (pt) método baseado em célula para determinar a potência de defibrotide
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
AR081765A1 (es) Composiciones farmaceuticas topicas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2012, OBSERVADAS AS CONDICOES LEGAIS.